Ripretinib

瑞派替尼

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameRipretinib
Drug Alias NameQinlock擎乐DCC-2618
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlatelet-derived growth factor receptor alpha inhibitorsStem cell growth factor receptor inhibitorsPlatelet-derived growth factor receptor beta inhibitors +[6] 
TargetsStem cell growth factor receptorPlatelet-derived growth factor receptor alphaPlatelet-derived growth factor receptor beta +[6] 
Therapy Area/IndicationsMastocytosis, SystemicGastrointestinal Stromal TumorsNeoplasms
Global Approved IndicationsGastrointestinal Stromal Tumors
Approved Indications in ChinaGastrointestinal Stromal Tumors
Original Approved Country/TerritoryUnited States
Original Approved Date2020/05/15
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDeciphera Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesMedison PharmaDeciphera PharmaceuticalsSpecialised Therapeutics Asia Pte Ltd +[6] 
Inactive CompaniesIqvia Rds (Shanghai) Co LtdBend Research Inc
Active IndicationsMastocytosis, SystemicGastrointestinal Stromal Tumors
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01XE
Related LinksWikipediaDrugBankKEGG